drugset

drugset / Trial / NCT06332430

Intratumoral CAN2109 in Subjects With Solid Tumors

NCT06332430 ↗

Phase 1 Recruiting 27 enrolled Canwell Biotech Limited

NaSingle-groupOpen-labelTreatment

Summary

A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.

Timeline

Start: 2024-05-28
Primary completion: 2025-05-30
Completion: 2026-05-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAN2109	Unknown	—	Other

Indications